Literature DB >> 3300326

Suppression of plasma renin activity by cyclosporine.

J P Bantle, R J Boudreau, T F Ferris.   

Abstract

Cyclosporine treatment is associated with hypertension and suppression of plasma renin activity, the causes of which are unclear. To determine whether suppressed plasma renin activity is due to extracellular fluid volume expansion, 10 cyclosporine-treated renal transplant recipients were compared with 10 azathioprine-treated renal transplant recipients and seven patients with renal insufficiency. Glomerular filtration rate and effective renal plasma flow were significantly lower in cyclosporine-treated patients than in azathioprine-treated patients. Upright plasma renin activity was suppressed in cyclosporine-treated patients (cyclosporine 2.9 +/- 0.9, azathioprine 4.7 +/- 0.9, renal insufficiency 5.2 +/- 1.9 ng/ml/hour) but could be stimulated by a four-day period of dietary sodium restriction and diuretic administration (cyclosporine 15.8 +/- 4.4 ng/ml/hour). Extracellular fluid volume tended to be higher in cyclosporine-treated patients (cyclosporine 30.7 +/- 2.3, azathioprine 26.7 +/- 2.5, renal insufficiency 25.5 +/- 1.4 percent lean body mass), although the difference between cyclosporine-treated and azathioprine-treated patients did not attain statistical significance. There were no differences in the urinary excretion of prostaglandin E2 or 6-keto prostaglandin F1 alpha between the two groups of renal transplant recipients. It is concluded that suppression of plasma renin activity by cyclosporine is physiologic and may reflect expansion of extracellular fluid volume, which can be reversed by sodium depletion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300326     DOI: 10.1016/0002-9343(87)90497-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-29       Impact factor: 8.237

Review 2.  The use of cyclosporin A in adult nephrotic syndrome: nine cases and literature review.

Authors:  A Green; Y O'Meara; J Sheehan; M Carmody; G Doyle; J Donohoe
Journal:  Ir J Med Sci       Date:  1990-06       Impact factor: 1.568

Review 3.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 4.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

5.  Acute cardiovascular effects of intravenous cyclosporine.

Authors:  J F Navarro; C Mora; R Marcén; J L Teruel; C Gámez; J J Jiménez; L Orofino; J Ortuño
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

6.  Acute and chronic renal failure in liver transplantation.

Authors:  J McCauley; D H Van Thiel; T E Starzl; J B Puschett
Journal:  Nephron       Date:  1990       Impact factor: 2.847

Review 7.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

8.  Mechanisms of hypertension during and after orthotopic liver transplantation in children.

Authors:  S Lawless; D Ellis; A Thompson; D R Cook; C Esquivel; T Starzl
Journal:  J Pediatr       Date:  1989-09       Impact factor: 4.406

9.  [Kidney function of patients with healthy kidneys during cyclosporin treatment].

Authors:  P Heering; B Kutkuhn; G Kreuzpaintner; T Reinhard; R Sundmacher; B Grabensee
Journal:  Klin Wochenschr       Date:  1991-11-26

10.  HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension.

Authors:  Monika Niehof; Jürgen Borlak
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.